INVAInnoviva, Inc.
Pharmaceutical Preparations
- Revenue
- $411M
- 15% YoY
- Operating margin
- 39.8%
- 14% YoY
- EBITDA
- $164M
- 1.9% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.9×
- −$313M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear2% of revenueOver 10% of revenue
- Payouts exceed cash flowClear2% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $392M | $331M | $310M | $359M | $411M | 15% |
| Operating income | $375M | — | $114M | $167M | $164M | 1.9% |
| Operating cash flow | $364M | $202M | $141M | $189M | $197M | 4.4% |
| Capex | $0 | $67K | $411K | $270K | $1M | 319% |
| Stock-based comp | $2M | $7M | $6M | $6M | $9M | 48% |
| Buybacks | $394M | $9M | $76M | $15M | $5M | 69% |
| Dividends | $0 | — | — | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
No pay-versus-performance disclosure yet.